Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Inflectra

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background In the light of scientific data, the medical and pharmaceutical community (rheumatology, gastroenterology, internal… Expand
Is this relevant?
2017
2017
Background Infliximab ('Remicade') has been authorized in the EU since 1999. It has a license for use in major rheumatic diseases… Expand
Is this relevant?
2017
2017
Background: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy for… Expand
Is this relevant?
2016
2016
Background The first infliximab (IFX) biosimilar (CT-P13) in Europe is marketed as two brand names, Inflectra (IFT) and Remsima… Expand
Is this relevant?
2016
2016
Background Biosimilars of infliximab have been recently introduced in clinical practice in inflammatory bowel disease (IBD) when… Expand
Is this relevant?
2016
2016
Introduction Switching from an established biologic to a biosimilar to save costs was considered likely to be ‘inappropriate and… Expand
Is this relevant?
2016
2016
The criterion adopted by EMA for approving biosimilars is that these agents must be supported by a comparability exercise; at the… Expand
  • table 1
Is this relevant?
2016
2016
Introduction CT-P13 is the biosimilar Infliximab approved for use in Europe and it is marketed in the UK in two brand names… Expand
Is this relevant?
2016
2016
  • Nature Biotechnology
  • 2016
  • Corpus ID: 205268225
455 Remicade in Europe, saw sales of the drug drop to $1.79 billion last year from $2.3 billion in the previous year. In a… Expand
Is this relevant?
2016
2016
  • 2016
  • Corpus ID: 160018782
WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. • Increased risk of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?